Previous 10 | Next 10 |
NES-ZIONA, ISRAEL / ACCESSWIRE / April 14, 2023 / This month, H.C. Wainwright & Co. reiterated its buy rating for Enlivex Therapeutics Ltd. (NASDAQ:ENLV) with a 12-month price target of $15 per share, based on a valuation estimated at $320 million. Despite forecasting a net loss of $1....
NES-ZIONA, ISRAEL / ACCESSWIRE / April 12, 2023 / This month, Enlivex Therapeutics Ltd . (NASDAQ:ENLV) announced a new clinical collaboration agreement with Beigene Ltd to test a new combination treatment to fight advanced-stage solid tumors. The therapy will combine Allocetra, Enlivex's ...
2023-04-10 08:55:07 ET OncoSec Medical ( ONCS ) +65%.GlucoTrack ( GCTK ) +29%.Guardforce AI ( GFAI ) +22%.Eloxx Pharmaceuticals ( ELOX ) +15%.Cocrystal Pharma ( COCP ) +13% on completing $4 Million private placement priced at-the-market under Nasdaq rules.Enlivex Therape...
2023-04-04 12:51:54 ET Gainers: Cardlytics ( CDLX ) +62% . Assure Holdings ( IONM ) +56% . The NFT Gaming Company ( NFTG ) +42% . Bullfrog AI Holdings ( BFRG ) +32% . Bellerophon Therapeutics ( BLPH ) +27% . Austin Gold ( A...
C linical collaboration with BeiGene announced on April 3 , 2023 to evaluate the safety and efficacy of Allocetra™, an investigational macrophage-reprogramming cell therapy, in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for the treatmen...
Nes-Ziona, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, today announced a clinical collaboration with BeiGene. to evaluate the safety and efficacy of Allocetra™...
Nes-Ziona, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that an independent Data and Safety Monitoring Board (DSMB) has completed an interim data r...
Enlivex Therapeutics ( NASDAQ: ENLV ) said that the Spanish Agency of Medicines and Medical Devices (AEMPS) authorized the expansion of its phase 1/2 trial of Allocetra in patients with advanced solid malignancies. The greenlight from the Spanish agency comes on the heels of simi...
Nes-Ziona, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Spanish Agency of Medicines and Medical Devices (AEMPS) has authorized the ex...
Nes-Ziona, Israel, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of an Israeli patent, numbered 284985, entitled, “Combination Immune The...
News, Short Squeeze, Breakout and More Instantly...
Enlivex Therapeutics Ltd. Company Name:
ENLV Stock Symbol:
NYSE Market:
Enlivex Therapeutics Ltd. Website:
First patient dosed with Allocetra TM in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects millions of people Thumb osteoarthritis currently has no FDA-approved therapy and no effective long-term treatments Ness-Ziona, Israel, June 24, 2024 (GLO...
Ness-Ziona, Israel, June 20, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a webinar on June 25, 2024, at 4:15 p.m...
Key Highlights Enrolled patients with severe knee osteoarthritis who were indicated for knee-replacement surgery received a single local injection of Allocetra TM into the knee as a “last resort” Three-month data readout showed a significant reduction in pain and a f...